Thesis: fraud, analyst: hithawk-research, sector: medicine.
see below
More ... latest change: 2026-02-28
Key Issues Evidence of a constructed fraud shell: Anbio’s structure, addresses, products, and filings consistently fail basic verification. Market manipulation indicators: Share inflation, fake investors, and dramatic stock swings point to an orchestrated pump-and-dump cycle. Regulatory noncompliance risks: Misleading disclosures, nonexistent operations, and false corporate information signal potential SEC and Nasdaq violations. Investor Takeaways Anbio lacks real business substance—no facilities, no supply chain, and likely fabricated products. Insider-controlled structure and suspicious investors suggest the IPO enriched a small circle at public expense. Extreme price volatility is engineered, not market-driven, making the stock highly dangerous for retail investors.
Last updated: 2026-03-07 by automated standardization process